Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17287341 | 0.96 | HSD17B10 (0.53) | HSD17B10GLAKDM4ETSHRALOX15 | |
| Ammonia Solution, Strong SCHEMBL5494411 | 0.86 | HSD17B10 (0.44) | HSD17B10KDM4ETSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL12534301 | 0.79 | HSD17B10 (0.38) | HSD17B10GLAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL3037700 | 0.76 | GSK3A (0.42) | TSHRLMNAALDH1A1 | |
| SCHEMBL13104001 | 0.75 | HSD17B10 (0.43) | HSD17B10KDM4ETSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL529016 | 0.75 | HSD17B10 (0.43) | HSD17B10KDM4ETSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL3042153 | 0.74 | KDM4E (0.45) | GLAKDM4ESMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1708734 | 0.74 | — | — | |
| SCHEMBL7289691 | 0.74 | — | — | |
| SCHEMBL28280267 | 0.73 | HSD17B10 (0.39) | HSD17B10KDM4ESMN1; SMN2ALDH1A1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651237-A4 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | JOHNSON & JOHNSON CONSUMER (US) | 2008-10-01 | — | — | EP | claimed |
| EP-1651237-A2 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | Galileo Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005016270-A2 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | GALILEO PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050032751-A1 | Methods for treatment of dermatological conditions | JOHNSON & JOHNSON CONSUMER INC. | 2005-02-10 | — | — | US | claimed |
| US-20230266675-A1 | INSPECTION METHOD, METHOD FOR PRODUCING COMPOSITION, AND METHOD FOR VERIFYING COMPOSITION | FUJIFILM CORPORATION (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230266675-A1 | INSPECTION METHOD, METHOD FOR PRODUCING COMPOSITION, AND METHOD FOR VERIFYING COMPOSITION | FUJIFILM CORPORATION (JP) | 2023-08-24 | — | — | US | disclosed |
| US-11703758-B2 | Photosensitive composition for EUV light, pattern forming method, and method for manufacturing electronic device | FUJIFILM CORPORATION (JP) | 2023-07-18 | — | — | US | disclosed |
| US-11703758-B2 | Photosensitive composition for EUV light, pattern forming method, and method for manufacturing electronic device | FUJIFILM CORPORATION (JP) | 2023-07-18 | — | — | US | disclosed |
| WO-2021241292-A1 | ACTIVE-RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTIVE-RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, PATTERN FORMATION METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | 富士フイルム株式会社 | 2021-12-02 | — | — | WO | disclosed |
| WO-2021065450-A1 | ACTIVE LIGHT SENSITIVE OR RADIATION SENSITIVE RESIN COMPOSITION, ACTIVE LIGHT SENSITIVE OR RADIATION SENSITIVE FILM, PATTERN FORMING METHOD, AND METHOD FOR PRODUCING ELECTRONIC DEVICE | 富士フイルム株式会社 | 2021-04-08 | — | — | WO | disclosed |
| US-20210011377-A1 | PHOTOSENSITIVE COMPOSITION FOR EUV LIGHT, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2021-01-14 | — | — | US | disclosed |
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2017040304-A1 | MALT1 INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-1651237-B1 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | JOHNSON & JOHNSON CONSUMER (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20100202989-A1 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | WANG BING | 2010-08-12 | — | — | US | disclosed |
| US-7737179-B2 | Methods for treatment of dermatological conditions | J&J CONSUMER COMPANIES, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1651237-A4 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | JOHNSON & JOHNSON CONSUMER (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1651237-A2 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | Galileo Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005016270-A2 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | GALILEO PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050032751-A1 | Methods for treatment of dermatological conditions | JOHNSON & JOHNSON CONSUMER INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100202989-A1 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | KRT18, CUTA, TUBB1 | HSD17B10 421/4885GLA 19/4885KDM4E 1588/4885 |
| US-20050032751-A1 | Methods for treatment of dermatological conditions | KRT18, CUTA, TUBB1 | HSD17B10 421/4885GLA 19/4885KDM4E 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.